Woodford Patient Capital Trust (Ordinary Share) WPCT

UK Growth

Estimated NAV

100.00

Share Price

95.80

Total Returns on £1000 over

5 years3 years1 year

Fund / Benchmark	Total returns(%)
Woodford Patient Capital Trust (Ordinary Share) Price	-1.97%
Woodford Patient Capital Trust (Ordinary Share) NAV	3.77%
FTSE All-Share Index	10.96%

Share Type	Yesterday's Closing Price	Discount / Premium	Diluted NAV		Gearing	Dividend
Share Type	Yesterday's Closing Price	Discount / Premium	Est	Last	Gearing	Dividend
Ordinary Share	96.3	-4.1%	100.00	101.00 20 Sep	112%	0.25%

Discrete performance % over

5 years3 years1 year

Fund / Benchmark	Q1	Q2	Q3	Q4
Woodford Patient Capital Trust (Ordinary Share) Price	-1.97
Woodford Patient Capital Trust (Ordinary Share) NAV	3.77
FTSE All-Share Index	10.96

Discrete performance over

5 years3 years1 year

Prothena Corp PLC	12.22%
Purplebricks Group PLC	9.31%
Oxford Nanopore Technologies	7.37%
Immunocore A	6.27%
Theravance Biopharma Inc	5.03%
Proton Partners International	3.52%
Mereo Bipharma	3.46%
Oxford Science Innovations	2.82%
Atom Bank	2.41%
Gigaclear	2.30%

Objective:
To achieve long-term capital growth through investing in a diversified portfolio with a focus on UK companies, both quoted and unquoted. The company will aim to deliver a return in excess of 10% p.a. over the longer term.

Neil Woodford Start: 21 Apr 2015

Paul Lamacraft Start: 21 Apr 2015

Saku Saha Start: 21 Apr 2015

Stephen Lamacraft Start: 21 Apr 2015

Management Contract & Fees:

Woodford Investment Management does not receive a management fee from the Company for its services and is only awarded a fee based on performance. The performance fee equals to 15% of any excess returns over a 10% hurdle rate per annum, subject to a high watermark. The majority of any performance fee is payable in Ordinary shares.